XML 122 R109.htm IDEA: XBRL DOCUMENT v3.22.4
SEGMENT INFORMATION Profitability (Details)
$ in Millions
12 Months Ended
Oct. 31, 2022
USD ($)
segment
Oct. 31, 2021
USD ($)
Oct. 31, 2020
USD ($)
Segment Reporting [Abstract]      
Number of operating segments | segment 3    
Select income statement components      
Net revenue $ 6,848 $ 6,319 $ 5,339
Income from operations 1,618 1,347 846
Depreciation expense 120 122 119
Share-based compensation $ 125 $ 110 $ 83
Revenue Benchmark      
Select income statement components      
Percentage of revenue from a single customer No customer represented 10 percent or more of our total net revenue No customer represented 10 percent or more of our total net revenue No customer represented 10 percent or more of our total net revenue
Life Sciences and Applied Markets      
Select income statement components      
Net revenue $ 4,007 $ 3,663 $ 3,115
Income from operations 1,186 1,017 792
Depreciation expense 59 60 58
Share-based compensation 69 60 46
Diagnostics and Genomics      
Select income statement components      
Net revenue 1,389 1,296 1,047
Income from operations 301 273 192
Depreciation expense 39 39 39
Share-based compensation 25 22 17
Agilent CrossLab      
Select income statement components      
Net revenue 1,452 1,360 1,177
Income from operations 370 323 272
Depreciation expense 22 23 22
Share-based compensation 26 24 18
Segment Total      
Select income statement components      
Net revenue 6,848 6,319 5,339
Income from operations 1,857 1,613 1,256
Depreciation expense 120 122 119
Share-based compensation $ 120 $ 106 $ 81